Paris, November 4, 2009 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad® at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 – November 1st).
The additional results from BioAlliance Pharma’s pivotal Phase III study with miconazole Lauriad® mucoadhesive buccal tablets (MBT) demonstrated comparable efficacy and safety profile to that of clotrimazole troches (administered five times per day) for oropharyngeal candidiasis (OPC), in HIVpositive patients in 40 sites in the United States, Canada and South Africa. The data also demonstrated a good patient compliance as a result of the added convenience of a once-a-day dosing.
This presentation was given by Dr Rajesh V. Lalla, oral medicine specialist, from the University of Connecticut Health Center.
OPC, also known as thrush, is an oral fungal infection most common in individuals with weakened immune systems – particularly those with HIV/AIDS and those undergoing cancer treatments. OPC is a disruptive condition that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, burning and/or altered taste.
About IDSA The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.
About BioAlliance Pharma As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs.
BioAlliance Pharma SA Dominique Costantini MD, President and CEO Tel.: +33 1 45 58 76 01 dominique.costantini@bioalliancepharma.com Nicolas Fellmann, CFO Tel.: +33 1 45 58 71 00 nicolas.fellmann@bioalliancepharma.com ALIZE RP Caroline Carmagnol Tel.: +33 6 64 18 99 59 caroline@alizerp.com
